MONTRÉAL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (CSE: CDPR) (OTCPK: GPPRF) (FRA: N8HP) (“CDPR” or the “Company”) is pleased to report that its 40-hole, Phase 1 drilling program at the Quiulacocha Tailings Project (“QT Project”) is now nearing completion. Key Highlights Drillhole SPT04 intersected 19 meters at 1.91 Oz/t (59g/t) […]

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni

LAS VEGAS, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) — One World Products, Inc. (the “Company”) (OTCQB: OWPC), a Nevada-based leader in sustainable industrial hemp solutions, recently showcased fully validated hemp-based molded containers – developed for an initial order of 1,400 units from Flex-N-Gate, a tier 1 supplier to the automotive industry. These production-ready reusable containers,

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announced that its subsidiary, ZenaDrone, has begun the first US trial of the IQ Nano product solution for inventory management, beginning with a multinational auto part and

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and

FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ: CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr.

WAYNE, PA., Oct. 15, 2024 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced two poster presentations at the upcoming 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference,

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today that it will host a conference call to discuss its 2024 third quarter financial results on Wednesday, October 23, 2024 at 10:00 a.m. (EDT). Prepared remarks regarding the results will be followed by a question-and-answer session with the senior management team. The

MONTRÉAL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the third quarter of 2024 on November 7, 2024. Financial results for the third quarter 2024 Eric Martel, President and Chief Executive Officer, Bombardier, and Bart Demosky, Executive Vice President and Chief Financial Officer, Bombardier, will present the financial